著者

Takao Fujisawa Terufumi Shimoda Keisuke Masuyama Kimihiro Okubo Kohei Honda Mitsuhiro Okano Toshio Katsunuma Atsuo Urisu Yasuto Kondo Hiroshi Odajima Kazuyuki Kurihara Makoto Nagata Masami Taniguchi Shoichiro Taniuchi Satoru Doi Tomoshige Matsumoto Shoji Hashimoto Akihiko Tanaka Kensuke Natsui Nahoko Abe Hideki Ozaki

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.67, no.3, pp.347-356, 2018 (Released:2018-07-28)

参考文献数

49

被引用文献数

7

---

Background: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.Methods: Japanese patients aged 5-65 years were eligible for the study, if they had HDM-induced allergic rhinitis (AR), allergic bronchial asthma (BA), or both. TO-204 was administered in a dose titration scheme, and the maintenance dose was determined according to the predefined criteria. The treatment period was 52 weeks, and patients who were willing to continue the treatment received TO-204 beyond 52 weeks. This clinical trial is registered at the Japan Pharmaceutical Information Center (Japic CTI-121900).Results: Between July 2012 and May 2015, 44 patients (28 with AR and 16 with allergic BA) were enrolled into the study. All patients were included in the analysis. The duration of treatment ranged from 23 to 142 weeks and the median maintenance dose was 200 Japanese allergy units (JAU). Adverse events occurred in 22 patients (50%). The most common adverse event was local reactions related to the injection sites. Four patients experienced anaphylactic reactions when they were treated with the dose of 500 JAU. Two patients experienced anaphylactic shock with the doses of 1000 JAU at onset. These 6 patients could continue the study with dose reduction.Conclusions: Safety profile of TO-204 was acceptable in Japanese patients with HDM-induced AR or allergic BA. Higher doses should be administered carefully, because the risk of anaphylaxis increased at doses of 500 or 1000 JAU.

著者

岡野 光洋 Mitsuhiro Okano

雑誌

経済学論究 = The journal of economics of Kwansei Gakuin University (ISSN:02868032)

巻号頁・発行日

vol.71, no.2, pp.119-140, 2017-09-20

著者

Syuji Yonekura Yoshitaka Okamoto Daiju Sakurai Toshioki Sakurai Tomohisa Iinuma Heizaburou Yamamoto Toyoyuki Hanazawa Shigetoshi Horiguchi Yuichi Kurono Kohei Honda Yuichi Majima Keisuke Masuyama Noriaki Takeda Shigeharu Fujieda Mitsuhiro Okano Satoshi Ogino Kimihiro Okubo

出版者

一般社団法人日本アレルギー学会

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.66, no.3, pp.425-431, 2017 (Released:2017-07-25)

参考文献数

38

被引用文献数

13

---

Background: Complementary and alternative medicine (CAM) is extensively used in patients with allergic diseases worldwide. The purpose of this study was to investigate the actual situation of CAM practice in the treatment of allergic rhinitis.Methods: We distributed questionnaires to otolaryngologists at 114 facilities in Japan. The subjects who participated in this study included children <16 years of age and adults ≥16 years of age diagnosed with allergic rhinitis by otolaryngologists. The survey was performed in the period from September 2007 to August 2009. Furthermore, we performed the same investigation out of the hospital setting, such as during general health examinations. All questionnaires were returned to Chiba University and analyzed.Results: The proportions of patients who had ever experimented with CAM in the hospital survey were 7.1% (225/3170) and 19.2% (1416/7363) of children and adults, respectively. Approximately 36.2% of the adult patients thought that the treatments were effective. The main reasons for CAM use were safety, convenience and low price. However, the group who spent more than $1000 on CAM felt more dissatisfaction and anxiety related to treatment at the hospital. The situation of CAM practice was not consistent and was instead influenced by the backgrounds of the subjects.Conclusions: Many patients who receive CAM report feeling that the effects of treatment provided by hospitals are insufficient and have concerns about the side effects of such treatments. Information regarding standard treatments, as described in the guidelines, should become widely known and diffused, and strong communication with patients should be considered.